Motohiro Tamiya

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 8

Top Topics

Epidermal Growth Factor Receptor

Top Venues

Investigational new drugs

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications (2024)
Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, Toshihide Yokoyama, Takeshi Uenami, Akihiro Tamiya, Yuki Sato, Go Saito, Junji Uchida, Mitsunori Morita, Tomonori Hirashima, Yasushi Fukuda, Masaki Kanazu, Kazutaka Hosoya, Takuji Suzuki, Kiyonobu Ueno, Daichi Fujimoto, Toru Kumagai, Satoshi Teramukai
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002. Investigational new drugs 40 (2) (2022)
Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki, Yoshihiko Taniguchi, Kanako Katayama, Shojiro Minomo, Keiko Nakao, Naoko Takeuchi, Yoshinobu Matsuda, Yujiro Naito, Takayuki Shiroyama, Norio Okamoto, Kyoichi Okishio, Toru Kumagai, Shinji Atagi, Fumio Imamura, Tomonori Hirashima
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. Investigational new drugs 39 (4) (2021)
Motohiro Tamiya, Kei Kunimasa, Kazumi Nishino, Shingo Matsumoto, Hayato Kawachi, Kika Kuno, Takako Inoue, Hanako Kuhara, Fumio Imamura, Koichi Goto, Toru Kumagai
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Investigational new drugs 39 (1) (2020)
Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, Seigo Ishii, Katsuya Hirano, Hirotaka Matsumoto, Yasushi Fukuda, Toshihide Yokoyama, Ryota Kominami, Daichi Fujimoto, Kazutaka Hosoya, Hidekazu Suzuki, Tomonori Hirashima, Masaki Kanazu, Nobuhiko Sawa, Junji Uchida, Mitsunori Morita, Takeshi Makio, Satoshi Hara, Toru Kumagai
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Investigational new drugs 38 (1) (2019)
Motohiro Tamiya, Akihiro Tamiya, Takako Inoue, Madoka Kimura, Kei Kunimasa, Kenji Nakahama, Yoshihiko Taniguchi, Takayuki Shiroyama, Shun-Ichi Isa, Kazumi Nishino, Toru Kumagai, Hidekazu Suzuki, Tomonori Hirashima, Shinji Atagi, Fumio Imamura
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. PloS one 13 (2) (2018)